Japanese startup uses AI to cross trade barriers
A Japanese company is using AI to bridge trade, language and culture gaps — one solution for a world where historic bonds are loosening, but consumer demand is as strong as ever.
Why it matters: If it works, it's a potential model for small businesses and creators around the world to access the U.S. market at a time of growing obstacles to international commerce.
Catch up quick: Monoya launched in late 2024 as a wholesaler of the work of Japanese artisans to the international home goods market.
Many of these artisans don't speak English, don't sell internationally and don't have a commercial infrastructure.
Yu Shimada, a former McKinsey consultant born in Japan and raised in New York, launched Monoya to bridge that gap. The company is backed by WAY Equity Partners, which invests in Japanese tech startups.
More than 90% of what it sells, Shimada says, isn't available in the U.S. market otherwise.
Driving the news: On Tuesday Monoya is taking the wraps off Monoya Connect, an AI sourcing platform to more directly connect sellers and buyers.
"The domestic market is shrinking, the one critical strategy we need to do is go outside of the country," Shimada told Axios.
The tool will provide a range of translation and design data services to more directly connect artisans and international vendors.
The intrigue: Shimada acknowledges AI is not perfect for all uses cases yet, — but the goal isn't to promote an AI platform, it's to use the technology as a tool.
"Having them understand this AI concept is not something I'm doing. I'm having them understand that with this tool it's going to solve their problems in a way, and we're using this thing called AI," he said.
Between the lines: Monoya is launching its new platform at a fraught time for global commerce, with the U.S. effectively charging the highest tariff rates in almost a century.
Shimada's argument is that a possible tariff isn't the biggest problem his sellers face — it's shipping, with rates rising around the world.
The bottom line: Even with rising trade pressures, Shimada said Japanese artisans can still be a solution for big U.S. brands.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan." Share Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.' About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.
Yahoo
3 hours ago
- Yahoo
North missed £140bn of transport investment over last government, research finds
The North of England would have received an extra £140 billion in transport investment under the previous government if funding levels had been the same as in London, research has claimed. Independent analysis by think tank the Institute for Public Policy Research (IPPR) looked at Treasury figures between 2009/10 and 2022/23, during which time the Conservatives were in power. It reached the figure, which it said was enough to build seven Elizabeth Lines, by considering the amount of spending per person across the different English regions over that period. While England as a whole saw £592 spent per person each year, London received double that amount with £1,183 spent per person, the IPPR said. The entire North region saw £486 spent per person, with the North East and North West seeing £430 and £540 spent per person respectively. This amounted to £140 billion of missed investment for the North, more than the entire £83 billion estimate of capital spending on transport in the region since 1999/2000, according to the analysis. The region with the lowest amount of investment over the period was the East Midlands with just £355 spent per person. Among the most divisive transport investment projects for the previous government was the HS2 rail project, which was axed north of Birmingham in October 2023. Then-prime minister Rishi Sunak pledged to 'reinvest every single penny, £36 billion, in hundreds of new transport projects in the North and the Midlands', including improvements to road, rail and bus schemes. Earlier this week, Chancellor Rachel Reeves announced a £15.6 billion package for mayoral authorities to use on public transport projects across the North and Midlands ahead of the spending review. It is expected to include funding to extend the metros in Tyne and Wear, Greater Manchester and the West Midlands, along with a renewed tram network in South Yorkshire and a new mass transit system in West Yorkshire. Marcus Johns, senior research fellow at IPPR North, said: 'Today's figures are concrete proof that promises made to the North over the last decade were hollow. It was a decade of deceit. 'We are 124 years on from the end of Queen Victoria's reign, yet the North is still running on infrastructure built during her rein – while our transport chasm widens. 'This isn't London bashing – Londoners absolutely deserve investment. But £1,182 per person for London and £486 for northerners? The numbers don't lie – this isn't right. 'This Government have begun to restore fairness with their big bet on transport cash for city leaders. 'They should continue on this journey to close this investment gap in the upcoming spending review and decades ahead.' Former Treasury minister Lord Jim O'Neill said: 'Good governance requires the guts to take a long-term approach, not just quick fixes. So the Chancellor is right in her focus on the UK's long-standing supply-side weaknesses – namely our woeful productivity and weak private and public investment. 'Backing major infrastructure is the right call, and this spending review is the right time for the Chancellor to place a big bet on northern growth and begin to close this investment chasm. 'But it's going to take more than commitments alone – she'll need to set out a transparent framework for delivery.'
Yahoo
7 hours ago
- Yahoo
Japanese Lunar Lander Crashes In Second Failed Mission
A private Japanese lunar lander crashed during an attempted touchdown on the moon Friday. This marks the second failed mission for the Tokyo-based global lunar exploration company, ispace. The lander, named Resilience, lost communication less than two minutes before its scheduled landing in Mare Frigoris, a flat, crater-filled region on the moon's northern near side. A preliminary analysis indicated the laser system for measuring altitude malfunctioned, causing the lander to descend too fast. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' ispace said in a statement. 'This is the second time that we were not able to land. So we really have to take it very seriously,' CEO and founder Takeshi Hakamada told reporters, per Associated Press. He apologized to contributors and added that the mission was 'merely a stepping stone' to a larger lander planned for 2027 with NASA involvement. 'Engineers did everything they possibly could' to ensure success, he said minutes before the attempted landing. The 7.5-foot Resilience, launched in January from Florida on a SpaceX rocket, carried an 11-pound, four-wheeled rover named Tenacious, built by ispace's Luxembourg subsidiary. The rover, equipped with a high-definition camera and a shovel for NASA to collect lunar soil, was designed to operate for two weeks during the moon's daylight period. It also carried a toy-size Swedish-style red cottage, dubbed Moonhouse by artist Mikael Genberg, for placement on the lunar surface. The mission's $16 million payload included scientific instruments from Japanese firms and a Taiwanese university. The failure follows ispace's first lunar crash in 2023, caused by inaccurate altitude readings. 'Truly diverse scenarios were possible, including issues with the propulsion system, software or hardware, especially with sensors,' Chief Technology Officer Ryo Ujiie said at a press conference. Jeremy Fix, chief engineer for ispace's U.S. subsidiary, noted last month that the company, with a mission cost less than the first's $100 million, lacks 'infinite funds' and cannot afford repeated failures. 'We're not facing any immediate financial deterioration or distress because of the event,' CFO Jumpei Nozaki said, citing investor support. However, space shares faced heavy sell orders and were poised for a 29% drop. As of Thursday, their market capitalization was over 110 billion yen ($766 million). The crash marks another setback in the commercial lunar race, which began in 2019. U.S. firms Firefly Aerospace and Intuitive Machines achieved successful landings in March, though Intuitive's lander toppled in a crater. Japan's space agency, JAXA, landed its SLIM probe last year, joining Russia, the U.S., China, and India as the only nations with successful robotic lunar landings. 'Expectations for ispace have not faded,' Japanese Prime Minister Shigeru Ishiba posted on X, reported Reuters. Ispace remains committed to NASA's Artemis program, with plans for a third mission in 2027. 'NASA increasingly needs private companies to improve cost efficiency for key missions with limited budgets,' Hakamada said, referencing proposed U.S. budget cuts. Two U.S. companies, Blue Origin and Astrobotic Technology, aim for moon landings by year's end following Astrobotic's 2024 failure.
